|Dr. Charles J. Fisher Jr.||CEO, Director & Member of Extracorporeal Therapy Advisory Board||124k||N/A||1947|
|Mr. James B. Frakes||CFO, Sr. VP of Fin. & Sec.||354.75k||N/A||1957|
|Mr. Guy F. Cipriani BS (Eng.), MBA||Sr. VP, Chief Bus. Officer & Director||34k||N/A||1971|
|Mr. Sunil Sawhney||Head of Clinical Studies||N/A||N/A||N/A|
|Mr. Steven P. Larosa||Chief Medical Officer||N/A||N/A||N/A|
|Dr. Richard H. Tullis||Consultant||N/A||N/A||1945|
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.
Aethlon Medical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.